Welcome to our dedicated page for Dexcom news (Ticker: DXCM), a resource for investors and traders seeking the latest updates and insights on Dexcom stock.
DexCom, Inc. reports news about its continuous glucose monitoring and glucose biosensing business for people with diabetes. Company updates commonly cover Dexcom G7 clinical evidence, product roadmap activity, U.S. and international revenue trends, margins, guidance, and presentations at diabetes technology and healthcare investor conferences.
Dexcom news also includes corporate governance developments, board appointments, management presentations, and long-term strategy discussions tied to its CGM portfolio, global commercialization, and innovation in metabolic health.
DexCom (NASDAQ:DXCM) announces that CEO Kevin Sayer will present an update at the 39th annual J.P. Morgan Healthcare Conference on January 11, 2021. The virtual presentation is set to begin at approximately 11:40 AM EST and will be available via a concurrent webcast.
Investors can access the webcast link through the Dexcom IR website under 'Events and Presentations.' DexCom is recognized for its innovative continuous glucose monitoring (CGM) systems, aiding diabetes management globally.
DexCom, Inc. (NASDAQ:DXCM) has announced management presentations at two upcoming virtual investor conferences. Steve Pacelli, Executive Vice President of Strategy and Corporate Development, will present at the Stifel Virtual Healthcare Conference on November 16, 2020, at 11:20 AM (EST) and at the Piper Sandler Healthcare Conference on December 1, 2020, at 3:00 PM (EST). Webcasts of these events will be available on the Dexcom Investor Relations website, where they will also be archived for future access.
DexCom, Inc. (NASDAQ:DXCM) will host an Investor Day on December 9, from 8:30 AM to 11:30 AM PST. The virtual event will feature presentations from management and industry leaders discussing market opportunities, business strategy, and long-term financial outlook.
The webcast will be available without pre-registration, accessible at dexcom2020investorday.com, and a replay will follow shortly after the event concludes.
DexCom, Inc. (NASDAQ:DXCM) will host an Investor Day on December 9, from 8:30 AM to 11:30 AM PST. The event will be virtual and feature presentations from management and industry leaders discussing the company’s market opportunities, business strategy, innovation, and long-term financial outlook. A live webcast will be available without pre-registration at dexcom2020investorday.com. A replay will be accessible shortly after the event concludes.
DexCom, Inc. (Nasdaq: DXCM) reported a robust 26% revenue growth in Q3 2020, reaching $500.9 million, driven by a 29% increase in U.S. sales and a 17% rise in international revenue. GAAP operating income was $94.1 million, reflecting an 18.8% operating margin, up 470 basis points year-over-year. The company raised its full-year revenue guidance to approximately $1.9 billion, indicating 29% growth. Notable highlights include the establishment of a CGM outcomes registry and a Patient Assistance Program for those affected by COVID-19. Cash reserves stand at $2.60 billion, ensuring financial flexibility.
DexCom, a leader in diabetes care technology, announced the retirement of Rick Doubleday, EVP and CCO, effective 2020, after significant contributions since 2009. Under his leadership, DexCom achieved $500.9 million in revenue for Q3 2020, marking a 26% growth year-over-year. Doubleday will continue as a consultant to aid the company's growth initiatives. The company plans to present its financial results on October 27, 2020. DexCom remains committed to enhancing diabetes management through innovative glucose monitoring systems.
DexCom, Inc. (NASDAQ: DXCM) has appointed Kyle Malady to its Board of Directors, effective immediately. Malady currently serves as executive vice president and chief technology officer at Verizon, overseeing global network operations and IT functions. With over 30 years of experience in mobile communications technology, Malady's extensive background is expected to enhance DexCom's leadership in continuous glucose monitoring and data analytics. His appointment aims to bolster DexCom’s efforts to empower diabetes management.
DexCom, Inc. (NASDAQ:DXCM) is set to release its third quarter 2020 financial results on October 27, 2020, after market close. A conference call will follow at 4:30 p.m. Eastern Time, where management will discuss the company's performance. Interested parties can access the call by dialing (800) 447-0521 (US/Canada) or (847) 413-3238 (International) with confirmation number '49260065'. DexCom is a leader in continuous glucose monitoring systems, dedicated to improving diabetes management for users, caregivers, and healthcare providers.